Alemtuzumab-induced Graves’ disease

Author:

Sheremeta M. S.1ORCID,Korchagina M. O.1ORCID,Guseinova R. M.1ORCID,Schmidt T. E.2ORCID,Nizhegorodova K. S.1ORCID,Sviridenko N. Yu.1ORCID,Melnichenko G. A.1ORCID

Affiliation:

1. Endocrinology Research Centre

2. I.M. Sechenov First Moscow State Medical University

Abstract

Multiple sclerosis (MS) is a severe chronic autoimmune demyelinating disease of the central nervous system, mediated by Th1/Th17 lymphocytes as well as B lymphocytes, macrophages and other immune cells. Some patients with MS are treated with alemtuzumab, a monoclonal antibody against CD52+ cells, which belongs to the disease-modifying therapies (DMTs). The main effect of alemtuzumab is related to changes in immune recruitment. Alemtuzumab therapy can induce secondary autoimmunity against the background of immune rebalancing. The thyroid gland is generally involved in the autoimmune process. Graves’ disease (GD) develops most often, followed by autoimmune thyroiditis.We present a clinical case of a patient with GD developed after alemtuzumab therapy for MS. The patient was referred to a radiologist at the Department of Radionuclide Therapy of Endocrinology Research Centre for radioiodine therapy (RAIT) due to relapse of thyrotoxicosis after anti-thyroid drug therapy for GD. The goal of treatment was achieved in 2 months, thyroid hormone therapy was initiated, against the background of this, there was compensation of thyroid function.

Publisher

Endocrinology Research Centre

Subject

Endocrinology, Diabetes and Metabolism

Reference32 articles.

1. Rassejannyj skleroz i drugie demielinizirujushhie zabolevanija. Ed. by Gusev EI, Zavalishin IA, Bojko AN. Moscow: Miklosh; 2004. — 540 p. (In Russ.).

2. Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018;8(9):a028928. doi: https://doi.org/10.1101/cshperspect.a028928

3. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain. 2008;131(Pt12):3118-3131. doi: https://doi.org/10.1093/brain/awn081

4. ‘t Hart BA, Hintzen RQ, Laman JD. Multiple sclerosis — a response-to-damage model. Trends Mol Med. 2009;15(6):235-244. doi: https://doi.org/10.1016/j.molmed.2009.04.001

5. Demina TL, Davydovskaja MV, Hachanova NV, i dr. Rassejannyj skleroz: patogenez, diagnostika, differencial’nyj diagnoz i lechenie. Consilium medicum. 2008;(1):61-68. (In Russ.).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3